<DOC>
	<DOCNO>NCT01854372</DOCNO>
	<brief_summary>To estimate I-year progression-free survival probability patient 70 year age previously untreated diffuse large B-celllymphoma ( DLBCL ) , intermediate ( Burkitt-like ) lymphoma , whose tumor cell show MYC rearrangement , treat alternate cycle Rituximab-HCV AD Rituximab-Methotrexate-Cytarabine , concert optimal supportive treatment include Pegfilgrastim , prophylactic antimicrobial , close clinical follow-up .</brief_summary>
	<brief_title>Rituximab-HyperCVAD ( R-HCVAD ) Alternating With Rituximab-Methotrexate-Cytarabine- ( R-MC ) Newly Diagnosed Patients With Diffuse Large B-Cell Lymphoma With MYC-Rearrangement .</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Lymphoma , Large B-Cell , Diffuse</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<criteria>1 . Diffuse large Bcell lymphoma intermediate ( `` Burkittlike '' ) lymphoma , newly diagnose excisional biopsy large core biopsy sufficient diagnostic material perform genetic test MYCR . 2 . Positivity MYCR Fluorescent insitu Hybridization ( FISH ) classical cytogenetics . 3 . No prior lymphoma treatment , one exception : One cycle RCHOP regimen permit ( consist one single dose Rituximab , cyclophosphamide , doxorubicine , vincristine , well 5 dos Prednisone part chemotherapy ) . 4 . No prior radiation therapy permit 5 . Age ≥ 18 year 70 year age 6 . CT image neck , chest , abdomen pelvis within 28 day prior registration . Any additional imaging use assess extent disease must also do within 28 day prior registration 7 . Bidimensionally measurable disease image within 28 day prior registration 8 . Adequate bone marrow biopsy , aspiration perform stag within 28 day registration , start treatment 9 . Indication primary treatment systemic multiagent chemotherapy 10 . Creatinine ≤ 2.0 mg/dL estimate ( CockroftGault ) creatinine clearance &gt; 50 ml/min within 7 day prior registration 11 . Cardiac ejection fraction ≥ 50 % MUGA scan 2D echocardiogram , well EKG without significant abnormality within 28 day prior registration 12 . Performance status 0 , 1 , 2 ( ECOG scale ) 13 . Patient willing , maintain , central venous line throughout treatment phase ( either PICC line , double lumen tunnel catheter , double lumen subcutaneous venous port system ) 14 . Willing logistically able follow outpatient least twice weekly , treatment phase . 15 . Signed informed consent accept transfusion blood product medically indicate 16 . Signed informed consent participate trial 1 . Age &gt; 70 year 2 . Leukemic presentation , evidence disease image 3 . Unwilling screen HIV . HIV positive patient must receive combined antiretroviral treatment study . They exclude participation unless show CD4 count &gt; 250/uL viral load &lt; 50 within 28 day registration . 4 . Hepatic involvement total serum bilirubin ≥ 5 mg/dL within 7 day prior registration , total serum bilirubin ≥ 1.6 mg/ dL without hepatic involvement within 7 day prior registration 5 . Patients bone marrow involvement either ANC &lt; 1000/uLor Platelets &lt; 50,000/uL , within 7 day registration 6 . Patients without bone marrow involvement lymphoma , either ANC &lt; 1500/uL Platelets &lt; 100,000/uL within 7 day registration 7 . Patients myelodysplastic syndrome , sickle cell disease , transfusion dependence 6 month antedate diagnosis oflymphoma . 8 . Known hypersensitivity E. coli derive protein 9 . Patients risk reactivation hepatitis B unwilling treat appropriate antiviral medically indicate . 10 . Pregnant nursing woman , patient reproductive potential unwilling use effective contraceptive method study start one year last dose protocol therapy . Adequate contraception define hormonal birth control , intrauterine device , double barrier method , total abstinence . 11 . Additional prior malignancy except adequately treat basal cell squamous cell skin cancer , situ cervical cancer , cancer patient diseasefree ~ 5 year 12 . Unwilling receive transfusion blood product medically indicate</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>December 2013</verification_date>
</DOC>